{"id":"ICC_Primary_Myelofibrosis_Diagnostic_Criteria.v0.0.1","gdl_version":"2.1","concept":"gt0001","language":{"original_language":"ISO_639-1::en"},"description":{"original_author":{"name":"Kevin Arjona","email":"kevin.arjona@cambio.se","organisation":"Cambio CDS","date":"2025-04-25"},"lifecycle_state":"Author draft","details":{"en":{"id":"en","copyright":"© Cambio CDS","keywords":["icc","international consensus classification","primary myelofibrosis"," pmf ","diagnostic criteria"],"purpose":"To assess whether the combination of recorded major and minor criteria meets the threshold for diagnosing PMF according to the ICC guidelines, based on data recorded in the OBSERVATION.icc_pmf_criteria archetype.","use":"The guideline checks if all 3 Major Criteria are met:\n\nCharacteristic BM morphology \n\nExclusion criteria met \n\nRequired Mutation/Marker status present \n\nAND if at least 1 Minor Criterion is met:\nAnemia present\n\nLeukocytosis > 11 x 10⁹/L \n\nPalpable splenomegaly present \n\nLDH level above ULN \n\nLeukoerythroblastosis present \n\nThe guideline outputs a determination of whether the overall ICC criteria for PMF diagnosis are met or not met.","misuse":"Does not provide the final diagnosis, only determines if the criteria are formally met based on the inputs. Clinical correlation is still required."}},"other_details":{"references":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gökbuget N, Gotlib J, Hellström-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Löwenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Döhner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-1228. doi: 10.1182/blood.2022015850. PMID: 35767897; PMCID: PMC9479031.","en":"Evaluates recorded findings against the International Consensus Classification (ICC, 2022) diagnostic criteria to determine if the criteria for Primary Myelofibrosis (PMF) are met."},"other_contributors":[]},"definition":{"data_bindings":{"gt0002":{"id":"gt0002","type":"INPUT","model_id":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0","template_id":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0","elements":{"gt0003":{"id":"gt0003","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0006]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0007|Yes|","local::at0008|No|"]},"gt0004":{"id":"gt0004","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0009]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0010|Yes|","local::at0011|No|"]},"gt0005":{"id":"gt0005","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0012]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0013|Yes|","local::at0014|No|"]},"gt0006":{"id":"gt0006","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0015]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0016|Yes|","local::at0017|No|"]},"gt0007":{"id":"gt0007","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0018]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0019|Yes|","local::at0020|No|"]},"gt0008":{"id":"gt0008","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0021]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0022|Yes|","local::at0023|No|"]},"gt0009":{"id":"gt0009","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0024]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0025|Yes|","local::at0026|No|"]},"gt0010":{"id":"gt0010","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0027]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0028|Yes|","local::at0029|No|"]},"gt0011":{"id":"gt0011","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0030]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0031|Yes|","local::at0032|No|"]},"gt0012":{"id":"gt0012","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0033]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0034|Yes|","local::at0035|No|"]},"gt0013":{"id":"gt0013","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0036]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0037|Yes|","local::at0038|No|"]}}},"gt0016":{"id":"gt0016","type":"OUTPUT","model_id":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0","template_id":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0","elements":{"gt0017":{"id":"gt0017","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0039]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0040|Meets criteria|","local::at0041|Does not meet criteria|"]},"gt0018":{"id":"gt0018","path":"/data[at0001]/events[at0002]/data[at0003]/items[at0042]","data_type":"DV_CODED_TEXT","allowed_values":["local::at0043|Meets criteria|","local::at0044|Does not meet criteria|"]}}}},"templates":{},"rules":{"gt0020":{"id":"gt0020","priority":4,"then":["$gt0017|PMF, Early/Prefibrotic Stage (Pre-PMF)| = local::at0041|Does not meet criteria|"],"when":["$gt0003|Bone marrow biopsy showing megakaryocytic proliferation and atypia, bone marrow fibrosis grade <2, increased age-adjusted BM cellularity, granulocytic proliferation, and decreased erythropoiesis| != local::at0007|Yes| || ( $gt0005|JAK2, CALR, or MPL mutation or presence of another clonal marker| != local::at0013|Yes| || $gt0006|Absence of reactive bone marrow reticulin fibrosis| != local::at0016|Yes| ) || $gt0008|Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met| != local::at0022|Yes| || ( $gt0009|Anemia not attributed to a comorbid condition| != local::at0025|Yes| && $gt0010|Leukocytosis ≥11 × 109/L| != local::at0028|Yes| && $gt0011|Palpable splenomegaly| != local::at0031|Yes| && $gt0012|Lactate dehydrogenase level above the reference range| != local::at0034|Yes| )"]},"gt0021":{"id":"gt0021","priority":3,"then":["$gt0018|PMF, Overt Fibrotic Stage| = local::at0044|Does not meet criteria|"],"when":["$gt0004|Bone marrow biopsy showing megakaryocytic proliferation and atypia, accompanied by reticulin and/or collagen fibrosis grades 2 or 3| != local::at0010|Yes| || ( $gt0005|JAK2, CALR, or MPL mutation or presence of another clonal marker| != local::at0013|Yes| || $gt0007|Absence of reactive myelofibrosis| != local::at0019|Yes| ) || $gt0008|Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met| != local::at0022|Yes| || ( $gt0009|Anemia not attributed to a comorbid condition| != local::at0025|Yes| && $gt0010|Leukocytosis ≥11 × 109/L| != local::at0028|Yes| && $gt0011|Palpable splenomegaly| != local::at0031|Yes| && $gt0012|Lactate dehydrogenase level above the reference range| != local::at0034|Yes| && $gt0013|Leukoerythroblastosis| != local::at0037|Yes| )"]},"gt0019":{"id":"gt0019","priority":2,"then":["$gt0017|PMF, Early/Prefibrotic Stage (Pre-PMF)| = local::at0040|Meets criteria|"],"when":["$gt0003|Bone marrow biopsy showing megakaryocytic proliferation and atypia, bone marrow fibrosis grade <2, increased age-adjusted BM cellularity, granulocytic proliferation, and decreased erythropoiesis| == local::at0007|Yes| && ( $gt0005|JAK2, CALR, or MPL mutation or presence of another clonal marker| == local::at0013|Yes| || $gt0006|Absence of reactive bone marrow reticulin fibrosis| == local::at0016|Yes| ) && $gt0008|Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met| == local::at0022|Yes|","$gt0009|Anemia not attributed to a comorbid condition| == local::at0025|Yes| || $gt0010|Leukocytosis ≥11 × 109/L| == local::at0028|Yes| || $gt0011|Palpable splenomegaly| == local::at0031|Yes| || $gt0012|Lactate dehydrogenase level above the reference range| == local::at0034|Yes|"]},"gt0022":{"id":"gt0022","priority":1,"then":["$gt0018|PMF, Overt Fibrotic Stage| = local::at0043|Meets criteria|"],"when":["$gt0004|Bone marrow biopsy showing megakaryocytic proliferation and atypia, accompanied by reticulin and/or collagen fibrosis grades 2 or 3| == local::at0010|Yes| && ( $gt0005|JAK2, CALR, or MPL mutation or presence of another clonal marker| == local::at0013|Yes| || $gt0007|Absence of reactive myelofibrosis| == local::at0019|Yes| ) && $gt0008|Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met| == local::at0022|Yes|","$gt0009|Anemia not attributed to a comorbid condition| == local::at0025|Yes| || $gt0010|Leukocytosis ≥11 × 109/L| == local::at0028|Yes| || $gt0011|Palpable splenomegaly| == local::at0031|Yes| || $gt0012|Lactate dehydrogenase level above the reference range| == local::at0034|Yes| || $gt0013|Leukoerythroblastosis| == local::at0037|Yes|"]}}},"ontology":{"term_definitions":{"en":{"id":"en","terms":{"gt0001":{"id":"gt0001","text":"ICC Primary Myelofibrosis Diagnostic Criteria","description":"Evaluates recorded findings against the International Consensus Classification (ICC, 2022) diagnostic criteria to determine if the criteria for Primary Myelofibrosis (PMF) are met."},"gt0002":{"id":"gt0002","text":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0"},"gt0003":{"id":"gt0003","text":"Bone marrow biopsy showing megakaryocytic proliferation and atypia, bone marrow fibrosis grade <2, increased age-adjusted BM cellularity, granulocytic proliferation, and decreased erythropoiesis"},"gt0004":{"id":"gt0004","text":"Bone marrow biopsy showing megakaryocytic proliferation and atypia, accompanied by reticulin and/or collagen fibrosis grades 2 or 3"},"gt0005":{"id":"gt0005","text":"JAK2, CALR, or MPL mutation or presence of another clonal marker"},"gt0006":{"id":"gt0006","text":"Absence of reactive bone marrow reticulin fibrosis"},"gt0007":{"id":"gt0007","text":"Absence of reactive myelofibrosis"},"gt0008":{"id":"gt0008","text":"Diagnostic criteria for ET, PV, BCR::ABL1-positive CML, myelodysplastic syndrome, or other myeloid neoplasms are not met"},"gt0009":{"id":"gt0009","text":"Anemia not attributed to a comorbid condition"},"gt0010":{"id":"gt0010","text":"Leukocytosis ≥11 × 109/L"},"gt0011":{"id":"gt0011","text":"Palpable splenomegaly"},"gt0012":{"id":"gt0012","text":"Lactate dehydrogenase level above the reference range"},"gt0013":{"id":"gt0013","text":"Leukoerythroblastosis"},"gt0016":{"id":"gt0016","text":"openEHR-EHR-OBSERVATION.icc_pmf_criteria.v0"},"gt0017":{"id":"gt0017","text":"PMF, Early/Prefibrotic Stage (Pre-PMF)"},"gt0018":{"id":"gt0018","text":"PMF, Overt Fibrotic Stage"},"gt0019":{"id":"gt0019","text":"Meet criteria for PMF, Early/Prefibrotic Stage (Pre-PMF)","description":""},"gt0020":{"id":"gt0020","text":" Does not meet criteria for PMF, Early/Prefibrotic Stage (Pre-PMF)","description":""},"gt0021":{"id":"gt0021","text":"Does not meet criteria for PMF, Overt Fibrotic Stage","description":""},"gt0022":{"id":"gt0022","text":"Meet criteria for PMF, Overt Fibrotic Stage","description":""}}}},"term_bindings":{}}}